Drug-Induced Movement Disorders: Emergencies and Management

2005, 1

Delay, 1960, Un neuroleptique majeur non phenothiazine et non reserpinique l’haloperidal dans le traitement des psychoses, Ann Med Pscyhol, 118, 145

Shalev, 1986, The neuroleptic malignant syndrome: agent and host interaction, Acta Psychiatr Scand, 50, 18

Caroff, 1988, Neuroleptic malignant syndrome, Psychopharmacol Bull, 24, 25

Shalev, 1989, Mortality from neuroleptic malignant syndrome, J Clin Psychiatry, 50, 18

Hasan, 1998, Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique, Am J Psychiatry, 115, 1113, 10.1176/ajp.155.8.1113

Caroff, 2001, Neuroleptic malignant syndrome, Adverse Drug React Bull, 209, 799, 10.1097/00012995-200108000-00001

Khan, 2006, Neuroleptic malignant syndrome, Neuroscience, 11, 104

Petzinger, 1997, A case of tetrabenazine-induced neuroleptic malignant syndrome after prolonged treatment, Mov Disord, 12, 246, 10.1002/mds.870120219

Washington, 1989, Amoxipine-induced neuroleptic malignant syndrome, DICP, 23, 713, 10.1177/106002808902300922

Gill, 2003, Acute lithium intoxication and neuroleptic malignant syndrome, Pharmacotherapy, 23, 811, 10.1592/phco.23.6.811.32179

Levenson, 1985, Neuroleptic malignant syndrome, Am J Psychiatry, 142, 1137, 10.1176/ajp.142.10.1137

Gurrera, 2010, Neuroleptic malignant syndrome diagnosis: an international consensus study using the Delphi technique, Eur Psychiatry, 25, 949, 10.1016/S0924-9338(10)70940-8

Caroff, 1993, Neuroleptic malignant syndrome, Med Clin North Am, 77, 202, 10.1016/S0025-7125(16)30278-4

Kipps, 2005, Movement disorder emergencies, Mov Disord, 20, 322, 10.1002/mds.20325

Alexander, 1998, Is risk of neuroleptic malignant syndrome increased in the postpartum period?, J Clin Psychiatry, 59, 254, 10.4088/JCP.v59n0509a

Otani, 1991, Is the predisposition to neuroleptic malignant syndrome genetically transmitted, Br J Psychiatry, 158, 850, 10.1192/bjp.158.6.850

Rosebush, 2008, Neuroleptic malignant syndrome and acute phase response, J Clin Psychopharmacol, 28, 459, 10.1097/JCP.0b013e31817ea9c1

Berman, 2011, Neuroleptic malignant syndrome: a review for neurohospitalists, The Neurohospitalist, 1, 41, 10.1177/1941875210386491

Rosenberg, 1989, Neuroleptic malignant syndrome: review of response to therapy, Arch Intern Med, 149, 1927, 10.1001/archinte.1989.00390090009002

Adnet, 2000, Neuroleptic malignant syndrome, Br J Anaesth, 85, 129, 10.1093/bja/85.1.129

Rosebush, 1989, Twenty neuroleptic rechallenges after neuroleptic malignant syndrome in 15 patients, J Clin Psychiatry, 50, 295

Caroff, 1998, Specific treatment of the neuroleptic malignant syndrome, Biol Psychiatry, 44, 378

Weiner, 1980, Drug holiday and management of Parkinson disease, Neurology, 30, 1257, 10.1212/WNL.30.12.1257

Sechi, 1984, Fatal hyperpyrexia after withdrawal from levodopa, Neurology, 34, 249, 10.1212/WNL.34.2.249

Friedman, 1985, A neuroleptic malignant-like syndrome due to levodopa therapy withdrawal, JAMA, 15, 2792, 10.1001/jama.1985.03360190098033

Factor, 2007, Fatal parkinsonism-hyperpyrexia syndrome in a Parkinson’s disease patient while actively treated with deep brain stimulation, Mov Disord, 22, 148, 10.1002/mds.21172

Ito, 2001, Neuroleptic malignant syndrome following withdrawal of amantadine in a patient with influenza a encephalopathy, Eur J Pediatr, 160, 401, 10.1007/s004310100743

Iwuagwu, 2000, Neuroleptic malignant-like syndrome in an elderly patient caused by abrupt withdrawal of tolcapone, a catechol-O-methyl transferase inhibitor, Am J Med, 108, 517, 10.1016/S0002-9343(99)00329-0

Reimer, 2002, Neuroleptic malignant-like syndrome after rapid switch from bromocriptine to pergolide, Parkinsonism Relat Disord, 9, 115, 10.1016/S1353-8020(01)00045-1

Kuno, 1997, Neuroleptic malignant syndrome in parkinsonian patients: risk factors, Eur Neurol, 38, 56, 10.1159/000113484

Sato, 2003, Efficacy of methylprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson’s disease, J Neurol Neurosurg Psychiatry, 74, 574, 10.1136/jnnp.74.5.574

Factor SA, Weiner WJ. Movement disorders emergencies: adults and children. American Academy of Neurology, 61st Annual Meeting. Seattle, WA, April 25–May 2, 2009.

Sternbach, 1991, The serotonin syndrome, Am J Psychiatry, 148, 705, 10.1176/ajp.148.6.705

Oates, 1960, Neurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitor, Neurology, 10, 1076, 10.1212/WNL.10.12.1076

Mason, 2000, Serotonin syndrome. Presentation of 2 cases and review of the literature, Medicine, 79, 201, 10.1097/00005792-200007000-00001

Robottom, 2011, Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson’s disease, Patient Prefer Adherence, 5, 57, 10.2147/PPA.S11182

Alkhatib, 2010, Serotonin syndrome as a complication of fentanyl sedation during esophagogastroduodenoscopy, Dig Dis Sci, 55, 215, 10.1007/s10620-009-0711-x

Kirschner, 2010, Serotonin syndrome precipitated by fentanyl during procedural sedation, J Emerg Med, 38, 477, 10.1016/j.jemermed.2008.01.003

Radomski, 2000, An exploratory approach to the serotonin syndrome: an update of clinical phenomenology and revised diagnostic criteria, Med Hypotheses, 55, 218, 10.1054/mehy.2000.1047

Hall, 2003, Serotonin syndrome, Aust Prescr, 26, 62, 10.18773/austprescr.2003.044

Mills, 1997, Serotonin syndrome: a clinical update, Crit Care Clin, 13, 763, 10.1016/S0749-0704(05)70368-7

Okamoto, 2010, Electroconvulsive therapy as a potentially effective treatment for severe serotonin syndrome: two case reports, J Clin Psychopharmacol, 30, 350, 10.1097/JCP.0b013e3181df6130

Diederich, 1998, Drug-induced movement disorders, Neurol Clin, 16, 125, 10.1016/S0733-8619(05)70370-4

Pierre, 2005, Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management, Drug Saf, 28, 191, 10.2165/00002018-200528030-00002

van Harten, 1999, Acute dystonia induced by drug treatment, BMJ, 319, 623, 10.1136/bmj.319.7210.623

Lutz, 1976, Neuroleptic-induced akathisia and dystonia triggered by alcohol, JAMA, 236, 2422, 10.1001/jama.1976.03270220042034

Freed, 1981, Alcohol-triggered neuroleptic-induced tremor, rigidity, and dystonia, Med J Aust, 2, 44, 10.5694/j.1326-5377.1981.tb132069.x

Campbell, 2001, The management of acute dystonic reactions, Aust Prescriber, 24, 19, 10.18773/austprescr.2001.011

Lange, 2001, Cardiovascular complications of cocaine use, N Engl J Med, 345, 351, 10.1056/NEJM200108023450507

Brust, 2010, Substance abuse and movement disorders, Mov Disord, 25, 2010, 10.1002/mds.22599

Rylander, 1972, Psychosis and the punding and choreiform syndromes in addictions to central stimulant drugs, Psychiatry Neurol Neurchir, 75, 203

Derlet, 1989, Emergency department presentation of cocaine intoxication, Ann Emerg Med, 18, 182, 10.1016/S0196-0644(89)80111-8

Brody, 1990, Cocaine-related medical problems: consecutive series of 233 patients, Am J Med, 88, 325, 10.1016/0002-9343(90)90484-U

Randrup, 1967, Stereotyped activities produced by amphetamine in several species and man, Psychopharmacologia, 11, 300, 10.1007/BF00404607

Daras, 1994, Cocaine-induced choreoathetoid movements (crack-dancing), Neurology, 44, 751, 10.1212/WNL.44.4.751

Choy-Kwong, 1989, Dystonia related to cocaine withdrawal: a case report and pathogenic hypothesis, Neurology, 39, 996, 10.1212/WNL.39.7.996-a

Kumor, 1990, Cocaine withdrawal dystonia, Neurology, 40, 863, 10.1212/WNL.40.5.863

Weiner, 2001, Cocaine-induced persistent dyskinesias, Neurology, 56, 964, 10.1212/WNL.56.7.964

Lundh, 1981, An extrapyramidal choreiform syndrome caused by amphetamine addiction, J Neurol Neurosurg Psychiatry, 44, 728, 10.1136/jnnp.44.8.728

Pascual-Leone, 1990, Cocaine-associated multifocal tics, Neurology, 40, 999, 10.1212/WNL.40.6.999

Factor, 1988, Cocaine and Tourette’s syndrome, Ann Neurol, 23, 423, 10.1002/ana.410230431

Golden, 1976, Gilles de la Tourette’s syndrome following amphetamine administration, Dev Med Child Neurol, 16, 76, 10.1111/j.1469-8749.1974.tb02715.x

Kurlan, 2001, Treatment of ADHD in children with tics: a randomized controlled trial, Neurology, 58, 527

Brown, 1987, Multiple severe complications from recreational ingestion of MDMA (ecstasy), JAMA, 258, 780, 10.1001/jama.1987.03400060056021

Hinkelbein, 2003, Suicide attempt with high dose ecstasy, Anesthetist, 52, 51, 10.1007/s00101-002-0433-3

Regenthal, 1999, Survival after massive “ecstasy” (MDMA) ingestion, Intensive Care Med, 25, 640, 10.1007/s001340050920

Ames, 1993, Ecstasy, the serotonin syndrome, and neuroleptic malignant syndrome—a possible link?, JAMA, 269, 869, 10.1001/jama.1993.03500070049022

Grunau, 2010, Dantrolene in the treatment of MDMA-related hyperpyrexia: a systematic review, CJEM, 12, 435, 10.1017/S1481803500012598

Lauterbach, 1999, Hiccup and apparent myoclonus after hydrocodone: a review of the opiate-related hiccup and myoclonus literature, Clin Neuropharmacol, 22, 87, 10.1097/00002826-199903000-00004

Hershey, 1983, Meperidine and central neurotoxicity, Ann Intern Med, 98, 548, 10.7326/0003-4819-98-4-548

Kaiko, 1983, Central nervous system excitatory effects of meperidine in cancer patients, Ann Neurol, 13, 180, 10.1002/ana.410130213

Dougherty, 2002, Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine, Ann Pharmacol, 36, 1647, 10.1345/aph.1C091

Tissot, 2003, Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use, Anesthesiology, 98, 1511, 10.1097/00000542-200306000-00033

Latta, 2002, Meperidine: a critical review, Am J Ther, 9, 53, 10.1097/00045391-200201000-00010

Ahlskog, 2001, Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature, Mov Disord, 16, 448, 10.1002/mds.1090

Factor, 2000, Emergency department presentations of patients with Parkinson’s disease, Am J Emerg Med, 18, 209, 10.1016/S0735-6757(00)90023-8

Chou, 2001, Deteriorating parkinsonism and subdural hematomas, Neurology, 57, 1295, 10.1212/WNL.57.7.1295

Weiner, 1978, Respiratory dyskinesias: extrapyramidal dysfunction and dyspnea, Ann Intern Med, 88, 327, 10.7326/0003-4819-88-3-327

Pahwa, 2006, Practice parameter: treatment of Parkinson disease motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology, Neurology, 66, 983, 10.1212/01.wnl.0000215250.82576.87

Aarsland, 2000, Predictors of nursing home placement in Parkinson’s disease: a population-based, prospective study, J Am Geriatr Soc, 48, 938, 10.1111/j.1532-5415.2000.tb06891.x

Robottom, 2009, Parkinson’s disease dementia, Curr Psychiatry Rev, 5, 218, 10.2174/157340009788971128

Giladi, 2000, Risk factors for dementia, depression and psychosis in long-standing Parkinson’s disease, J Neural Transm, 107, 59, 10.1007/s007020050005

Mosimann, 2006, Characteristics of visual hallucinations in Parkinson disease dementia and dementia with Lewy bodies, Am J Geriatr Psychiatry, 14, 153, 10.1097/01.JGP.0000192480.89813.80

Friedman, 2000, Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson’s disease, Mov Disord, 15, 201, 10.1002/1531-8257(200003)15:2<201::AID-MDS1001>3.0.CO;2-D

Miyasaki, 2006, Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review), Neurology, 66, 996, 10.1212/01.wnl.0000215428.46057.3d

Robottom, 2011, Movement disorders emergencies part 1: hypokinetic disorders, Arch Neurol, 68, 567, 10.1001/archneurol.2011.84